直肠癌辅助治疗新进展演示文稿.pptVIP

直肠癌辅助治疗新进展;直肠癌的存活与分期;直肠癌VS结肠癌:存活相似;UFT辅助化疗改善III期直肠癌存活 日本 NSCS-CC7 试验 ASCO 2007 Abstr 4049;直肠癌术前术后辅助化放疗：复发与存活德国直肠癌研究组 NEJM 2006;直肠癌术后治疗与局部复发和存活;Outcome of preoperative chemotherapy (POC) in locally advanced rectal cancer (LARC): Meta-analysis of randomized clinical trials (RCT). ;Surrogate endpoints in neoadjuvant rectal cancer trials: Statistical evaluation using data from the FFCD 9203 trial ;Lymph node harvest and survival in rectal cancer.;直肠癌术后局部 复发率:7个随机试验;;3. 奥沙利铂联合卡培他滨同期化放疗pCR高。RTOG 0247研究（1）;3. 奥沙利铂联合卡培他滨同期化放疗pCR高。RTOG 0247研究（2）;伊立替康联合LV5-FU2：直肠癌辅助化疗French Intergroup R98 trial;4. 结肠癌辅助化疗的提示（1）：延迟辅助化疗导致生存益处下降;4. 结肠癌辅助化疗的提示（2）：提前中断辅助化疗导致生存率下降;5. 直肠癌术后辅助治疗 HB 浓度与存活;6. 接受术前辅助治疗,术后N0的直肠癌患者：术后辅助化疗同样有益。;肠系膜癌结节与III期结直肠癌的预后;错配修复与直肠癌术后辅助化疗：deficient mismatch repair (dMMR):A pooled molecular reanalysis of randomized chemotherapy trials. ;西妥昔单抗用于直肠癌辅助治疗：Prediction of pathological response to preoperative chemoradiotherapy with cetuximab in rectal cancer;Khambata-Ford, S. et al. J Clin Oncol; 25:3230-3237 2007; K-ras有助于调节细胞存活，增殖和分化，胰腺癌患者K-ras 突变率高达95%，NSCLC和CRC 30%。同VEGFR家族一样，K-ras参与MAPK增殖的信号通路。;PA.3 significant improvement in overall survival in patients with metastatic disease*;; K-ras突变可通过上调VEGF来调节血管生成，VEGF表达与K-ras密切相关。有75%的胰腺癌在高表达VEGF的同时有K-ras突变。K-ras突变伴有不良预后—中位存活短于K-ras野生型者。;贝伐单抗与直肠癌辅助治疗：Correlation of blood and physiologicmarker with effect of bevacizumab (BV) withchemoradiation therapy in rectal cancer ;直肠癌术后辅助治疗小结;直肠癌术后辅助治疗小结;